Covalent Bioscience, Inc. is producing Alzyme, a catalytic antibody (catabody) that destroys amyloid beta, a misfolded protein that forms Alzheimer’s plaques. The company is also developing prototype Tauzyme candidates to destroy misfolded tau protein, another amyloid implicated in Alzheimer’s disease.